Sun Pharma Advanced Research Co Ltd
NSE:SPARC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (75.3), the stock would be worth ₹123.26 (15% downside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 88.4 | ₹144.78 |
0%
|
| 3-Year Average | 75.3 | ₹123.26 |
-15%
|
| 5-Year Average | 64.2 | ₹105.19 |
-27%
|
| Industry Average | 3.8 | ₹6.15 |
-96%
|
| Country Average | 2.6 | ₹4.28 |
-97%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
₹41.4B
|
/ |
Jan 2026
₹531.4m
|
= |
|
|
₹41.4B
|
/ |
Mar 2026
₹623.3B
|
= |
|
|
₹41.4B
|
/ |
Mar 2027
₹665.3B
|
= |
|
|
₹41.4B
|
/ |
Mar 2028
₹740.4B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
S
|
Sun Pharma Advanced Research Co Ltd
NSE:SPARC
|
48.2B INR | 88.4 | -17.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 13.5 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 5.7 | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 4.9 | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 4.2 | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 5 | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.9 | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 2.4 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 2.5 | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.6 |
| 70th Percentile | 4.6 |
| Max | 56 363.4 |
Other Multiples
Sun Pharma Advanced Research Co Ltd
Glance View
Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2007-07-18. The firm is engaged in the business of research and development (R&D) of pharmaceutical products to meet unmet medical needs in the areas of oncology, neurodegeneration and immunology. The company develops new chemical entities (NCE), new biological entities (NDDS) and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its NDDS includes Wrap Matrix technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology, which is useful to develop controlled-release tablets. The firm has developed Elepsia XR, using Wrap Matrix technology. Lipexelle technology for ophthalmic formulations. The company has developed Xelpros, a BAK-free latanoprost eye drops developed using Lipexelle technology. Xelpros is commercialized by the Company’s partner in the United States. The company developed PDP-716 eye drops for the treatment of glaucoma based on its TearAct technology.
